Replies to post #230978 on Avid Bioservices Inc (CDMO)

[cheynew]

I think you're on thin ice claiming CJ and Lytle have done anything for PPHM other than cashing their exorbitant pay checks.

Don't forget Lytle had a hand in negotiating those banking contracts that allowed the onerous provisions.

Having credible board member (s) added could far outweigh the costs with Wall Street Credibility and a resultant increase in pps.

[jakedogman1]

"Believe me a FULL 8 or 12 member Bod would cost us MUCH MORE in total."

Wrong... on all accounts...

First there is no way one can justify the BOD pay.. three times Walmart, double APPLE, 75% more GILD?

The opportunity cost of such an terrible BOD is virtually no institutional interest other than index funds... Lack of institutional interest has kept the share price low..

The BOD has a history of self dealing and running companies into the ground and really no success stories to speak of.. IMO I think this could be a major problem in partnering? My guess is any BP would not want these clowns around.

No one on the BOD has biotech experience...how would they know what any deal looks like yet alone a good deal? What we do know is they milk a cash starved biotech that has to sell shares for 20% of development costs in order to pay themselves double what Apple directors get.

There is a reason they don't want oversight... and it's not a good one.

[itsabouttime]

CP Could not agree more with statement below but understand the anger/frustration the long term holders have.



I know why I stand behind this management: They stuck their necks out and provided PPHM with IP right that are crucial. Now that everything starts to come together and we have no more creditors, own our IP and pipelines 100% unencumbered and have a SUNRISE PIII trial close to approval, now we suddenly have a problem with compensation.

Believe me a FULL 8 or 12 member Bod would cost us MUCH MORE in total.

[Couch]

And even the staunchest of supporters such as yourself must be able to agree that a shareholder letter would do wonders for managements' wish to obtain yes votes on the Proxy.

To think that is not coming is at best confusing.

[biopharm]

- What about CEO King assigning his rights of the PS-targeting Patents to PPHM rather then to UTSW (as did P. Thorpe)?

- What about ES saving the money with his cash contributions when nobody else wanted to give PPHM a loan?

I could possibly follow the reasoning for Pohl, Carlton and our CFO.

We tend to forget when they do things for PPHM. We find it normal that UTSW gets compensated for the IP rights, but NOT CEO King. remarkable.
We find it normal that a banker rips PPHM of with interests, loan recall fees, etc but not that ES provides us the cash without all those troubles as he injected it in the capital AT the moment of the HIGHEST RISK for PPHM.
...
..

CP, good post and you mentioned SK assigning his rights of the PS Targeting patents to PPHM rather than UTSW .. ?

One wild departure was Troy Luster whom is also on some PS Targeting patents with the late Dr. Phil Thorpe, so did Troy assign his over to PPHM as well ?

----------------------------

Post-Doctoral Fellow
University of Texas Southwestern Medical Center
August 2003 – October 2007 (4 years 3 months)Dallas, TX

Department of Pharmacology - laboratory of the late Philip E. Thorpe, Ph.D.

Work focused on the generation of novel tumor vascular targeting agents for the treatment of solid tumor malignancies.

Determined that a novel phosphatidylserine-specific antibody required the co-factor beta2-glycoprotein I for binding. This work lead to a first author publication in The Journal of Biological Chemistry.

Developed novel dimeric beta2-glycoprotein I molecules to target phosphatidylserine exposed on tumor vasculature endothelial cells. This work lead to US patent #8,956,616 for "Betabody" technology being developed by Peregrine Pharmaceuticals.

Supported in 2006-2007 by an award from the American Cancer Society to study the anti-tumor effects of combining a novel anti-phosphatidylserine antibody with radiation therapy.

Work resulted in 1 first author publication, co-author on 5 additional papers.

https://www.linkedin.com/pub/troy-luster/55/685/39b